• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于实体肿瘤癌症的溴结构域和额外末端(BET)结构域蛋白抑制剂。

Bromodomain and Extra-Terminal (BET) Domain Protein Inhibitors for Solid Tumor Cancers.

作者信息

Nguyen Martin V, Loof Lydia, Falchook Gerald S

机构信息

Sarah Cannon Research Institute at HealthONE, Denver, CO, USA.

出版信息

J Immunother Precis Oncol. 2020 Feb 5;3(1):16-22. doi: 10.4103/JIPO.JIPO_2_20. eCollection 2020 Feb.

DOI:10.4103/JIPO.JIPO_2_20
PMID:35756176
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9208386/
Abstract

The bromodomain and extraterminal (BET) domain protein family is involved in the process of transcription of genetic information. The BET protein family includes BRD2, BRD3, BRD4, and bromodomain testis-specific protein. BET protein alterations are associated with some solid tumor cancers, including nuclear protein in testis midline carcinoma. BET protein has a role in carcinogenesis and in the regulation of the cell cycle. A number of BET inhibitors have entered clinical trials. This review discusses the results of BET inhibitor clinical trials in solid tumor cancers.

摘要

溴结构域和额外末端(BET)结构域蛋白家族参与遗传信息的转录过程。BET蛋白家族包括BRD2、BRD3、BRD4和睾丸特异性溴结构域蛋白。BET蛋白改变与一些实体肿瘤癌症相关,包括睾丸中线癌中的核蛋白。BET蛋白在致癌作用和细胞周期调控中发挥作用。多种BET抑制剂已进入临床试验。本综述讨论了BET抑制剂在实体肿瘤癌症临床试验中的结果。

相似文献

1
Bromodomain and Extra-Terminal (BET) Domain Protein Inhibitors for Solid Tumor Cancers.用于实体肿瘤癌症的溴结构域和额外末端(BET)结构域蛋白抑制剂。
J Immunother Precis Oncol. 2020 Feb 5;3(1):16-22. doi: 10.4103/JIPO.JIPO_2_20. eCollection 2020 Feb.
2
Comparative structure-function analysis of bromodomain and extraterminal motif (BET) proteins in a gene-complementation system.在基因互补系统中对溴结构域和末端结构域(BET)蛋白进行比较结构-功能分析。
J Biol Chem. 2020 Feb 14;295(7):1898-1914. doi: 10.1074/jbc.RA119.010679. Epub 2019 Dec 2.
3
Overexpression of Bromodomain and Extraterminal Domain is Associated with Progression, Metastasis and Unfavorable Outcomes: Highlighting Prognostic and Therapeutic Value of the BET Protein Family in Gastric Cancer.Bromodomain 和 Extraterminal 结构域的过表达与进展、转移和不良结局相关:强调 BET 蛋白家族在胃癌中的预后和治疗价值。
Anticancer Agents Med Chem. 2023;23(7):794-806. doi: 10.2174/1871520623666221025145320.
4
Systematic analysis of the BET family in adrenocortical carcinoma: The expression, prognosis, gene regulation network, and regulation targets.BET 家族在肾上腺皮质癌中的系统分析:表达、预后、基因调控网络和调控靶点。
Front Endocrinol (Lausanne). 2023 Jan 30;14:1089531. doi: 10.3389/fendo.2023.1089531. eCollection 2023.
5
The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins.溴结构域与额外末端结构域(BET)家族:BET 旁系同源蛋白的功能剖析
Int J Mol Sci. 2016 Nov 7;17(11):1849. doi: 10.3390/ijms17111849.
6
Small-Molecule Targeting of BET Proteins in Cancer.小分子靶向 BET 蛋白治疗癌症。
Adv Cancer Res. 2016;131:21-58. doi: 10.1016/bs.acr.2016.04.001. Epub 2016 May 31.
7
Bromodomain and extra-terminal inhibitors emerge as potential therapeutic avenues for gastrointestinal cancers.溴结构域和额外末端结构域抑制剂成为胃肠道癌症潜在的治疗途径。
World J Gastrointest Oncol. 2022 Jan 15;14(1):75-89. doi: 10.4251/wjgo.v14.i1.75.
8
The Role of Bromodomain and Extraterminal Motif (BET) Proteins in Chromatin Structure.溴结构域和额外末端基序(BET)蛋白在染色质结构中的作用。
Cold Spring Harb Symp Quant Biol. 2017;82:37-43. doi: 10.1101/sqb.2017.82.033829. Epub 2017 Dec 1.
9
Discovery of novel small molecule induced selective degradation of the bromodomain and extra-terminal (BET) bromodomain protein BRD4 and BRD2 with cellular potencies.新型小分子诱导的溴结构域和末端(BET)溴结构域蛋白 BRD4 和 BRD2 选择性降解的发现及其细胞效力。
Bioorg Med Chem. 2020 Jan 1;28(1):115181. doi: 10.1016/j.bmc.2019.115181. Epub 2019 Nov 11.
10
BET Bromodomain Inhibitors: Novel Design Strategies and Therapeutic Applications.BET 溴结构域抑制剂:新颖的设计策略和治疗应用。
Molecules. 2023 Mar 29;28(7):3043. doi: 10.3390/molecules28073043.

引用本文的文献

1
Novel Approach to Overcome Osimertinib Resistance Using Bromodomain and Extra-Terminal Domain Inhibitors.使用溴结构域和额外末端结构域抑制剂克服奥希替尼耐药性的新方法。
Cancer Sci. 2025 May;116(5):1392-1404. doi: 10.1111/cas.70032. Epub 2025 Mar 4.
2
Bromo- and Extra-Terminal Domain Inhibitors Induce Mitochondrial Stress in Pancreatic Ductal Adenocarcinoma.溴结构域和末端结构域抑制剂诱导胰腺导管腺癌中的线粒体应激。
Mol Cancer Ther. 2023 Aug 1;22(8):936-946. doi: 10.1158/1535-7163.MCT-23-0149.
3
Recent Advances in Glioma Cancer Treatment: Conventional and Epigenetic Realms.胶质瘤癌症治疗的最新进展:传统领域与表观遗传领域
Vaccines (Basel). 2022 Sep 2;10(9):1448. doi: 10.3390/vaccines10091448.

本文引用的文献

1
Bromodomain and extra-terminal motif inhibitors: a review of preclinical and clinical advances in cancer therapy.溴结构域和额外末端基序抑制剂:癌症治疗的临床前和临床进展综述
Future Sci OA. 2019 Jan 29;5(3):FSO372. doi: 10.4155/fsoa-2018-0115. eCollection 2019 Mar.
2
First-in-human phase I study of the bromodomain and extraterminal motif inhibitor BAY 1238097: emerging pharmacokinetic/pharmacodynamic relationship and early termination due to unexpected toxicity.首例人体 I 期研究:溴结构域和末端外结构域抑制剂 BAY 1238097:新出现的药代动力学/药效学关系和因意外毒性而提前终止。
Eur J Cancer. 2019 Mar;109:103-110. doi: 10.1016/j.ejca.2018.12.020. Epub 2019 Jan 31.
3
Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors.Birabresib 联合治疗晚期实体瘤的 Ib 期临床试验:一种新型小分子溴结构域和末端外结构域蛋白抑制剂
J Clin Oncol. 2018 Oct 20;36(30):3007-3014. doi: 10.1200/JCO.2018.78.2292. Epub 2018 May 7.
4
BET Proteins as Targets for Anticancer Treatment.BET 蛋白作为抗癌治疗的靶点。
Cancer Discov. 2018 Jan;8(1):24-36. doi: 10.1158/2159-8290.CD-17-0605. Epub 2017 Dec 20.
5
BET inhibitors: a novel epigenetic approach.BET 抑制剂:一种新的表观遗传方法。
Ann Oncol. 2017 Aug 1;28(8):1776-1787. doi: 10.1093/annonc/mdx157.
6
Functions of bromodomain-containing proteins and their roles in homeostasis and cancer.溴结构域蛋白的功能及其在维持体内平衡和癌症中的作用。
Nat Rev Mol Cell Biol. 2017 Apr;18(4):246-262. doi: 10.1038/nrm.2016.143. Epub 2017 Jan 5.
7
BET inhibitors in the treatment of hematologic malignancies: current insights and future prospects.BET抑制剂在血液系统恶性肿瘤治疗中的应用:当前见解与未来展望
Onco Targets Ther. 2016 Sep 28;9:5943-5953. doi: 10.2147/OTT.S100515. eCollection 2016.
8
AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies.AZD5153:一种新型双价 BET 溴结构域抑制剂,对血液系统恶性肿瘤具有高度活性。
Mol Cancer Ther. 2016 Nov;15(11):2563-2574. doi: 10.1158/1535-7163.MCT-16-0141. Epub 2016 Aug 29.
9
Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study.溴结构域抑制剂OTX015用于淋巴瘤或多发性骨髓瘤患者:一项剂量递增、开放标签、药代动力学1期研究。
Lancet Haematol. 2016 Apr;3(4):e196-204. doi: 10.1016/S2352-3026(16)00021-1. Epub 2016 Mar 18.
10
Inducible in vivo silencing of Brd4 identifies potential toxicities of sustained BET protein inhibition.体内诱导性沉默Brd4可确定持续抑制BET蛋白的潜在毒性。
Cell Rep. 2014 Sep 25;8(6):1919-1929. doi: 10.1016/j.celrep.2014.08.025. Epub 2014 Sep 18.